GU Cancers 2019 | KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

Arjun Balar

Relapse in patients after Bacillus Calmette-Guerin (BCG) treatment remains a concern. Here, Arjun Balar, MD, from NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses clinically meaningful results from the KEYNOTE-057 Phase II study of pembrolizumab therapy in HR non-muscle-invasive bladder cancer (NMIBC) patients unresponsive to BCG therapy (NCT02625961). Treatment of patients treated with pembrolizumab had encouraging antitumor activity as well as a low toxicity profile. Dr Balar explains that once the durability of responses to pembrolizumab is assessed, pembrolizumab therapy could become a promising treatment for BCG-unresponsive NMICB. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video